Seltorexant
Experimental drug candidate for sleep problems and depression that blocks the wakefulness signal of orexin; not yet approved.
Pharmacology
Contents
DETAILED OVERVIEW
What is Seltorexant?
Seltorexant is an experimental drug candidate that the pharmaceutical company Janssen is developing for sleep problems and major depression. It is not approved as a medicine in any country, it is not a dietary supplement, and it is used only within clinical trials.
In the brain, a messenger called orexin keeps a person awake; seltorexant blocks one of its receptors and largely spares the other. In studies people fell asleep faster, slept longer and stayed asleep better, and compared with placebo depression also eased, mainly where poor sleep was present as well. Side effects can include next-day drowsiness, headache, dizziness and tiredness. Together with alcohol and other sedating substances the drowsy effect adds up. It is contraindicated in narcolepsy (a condition involving a lack of orexin), and its safety in pregnancy and breastfeeding has not been established.
Mechanism
Selective OX2R antagonist
Half-life
~2-3 hours
Legal status
Investigational (Phase 3), not approved
No anecdote collected yet.
Receptor profile
- Orexin-2 receptor (OX2R)Strong
- Wakefulness drive suppressionStrong
- Orexin-1 receptor (OX1R, spared)Weak
Safety
Side effects, stop signs, contraindications
Side effects · 5
- Next-day grogginess, somnolence, occasionally residual sedation
- Headache
- Mild dizziness
- Mild fatigue
- Vivid dreams or sleep paralysis theoretically possible with orexin antagonists (rare)
Contraindications · 4
- Pregnancy and breastfeeding: safety not established, avoid
- Narcolepsy or other orexin-deficient states: further blockade of orexin signaling is contraindicated
- Additive sedation with other CNS depressants (alcohol, benzodiazepines, opioids)
- Investigational compound: not an approved medicine, not for use outside clinical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
Bonaventure P, Dugovic C, Shireman B, et al.
Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Savitz A, Wajs E, Zhang Y, et al.
Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant
Recourt K, de Boer P, van der Ark P, et al.
Characteristics of Seltorexant-Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety
Szmyd B, Karuga FF, et al.
Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial
Recourt K, et al.
FAQ
FAQ
Seltorexant is an investigational drug being studied for sleep problems and depression, particularly cases where poor sleep and depression occur together. It works by dialing down a brain signal that keeps you awake, helping you fall asleep faster and sleep more soundly. In trials it shortened time to fall asleep, improved total sleep time and mood, and was reported to be well tolerated. Important: this is still in clinical development, not an approved, marketed drug.
Telegram
Have a question about Seltorexant?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.